MX2022003159A - Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos. - Google Patents

Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos.

Info

Publication number
MX2022003159A
MX2022003159A MX2022003159A MX2022003159A MX2022003159A MX 2022003159 A MX2022003159 A MX 2022003159A MX 2022003159 A MX2022003159 A MX 2022003159A MX 2022003159 A MX2022003159 A MX 2022003159A MX 2022003159 A MX2022003159 A MX 2022003159A
Authority
MX
Mexico
Prior art keywords
methods
antibodies
stem cell
cell factor
factor antibodies
Prior art date
Application number
MX2022003159A
Other languages
English (en)
Inventor
Martin Phillips
Original Assignee
Opsidio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opsidio Llc filed Critical Opsidio Llc
Publication of MX2022003159A publication Critical patent/MX2022003159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención se relaciona con anticuerpos y fragmentos de unión al antígeno de ellos que se unen al factor de células madre (SCF). Los anticuerpos y los fragmentos de unión al antígeno de ellos se unen específicamente a SCF248. La invención además se relaciona con métodos para elaborar los anticuerpos y con métodos de uso de los anticuerpos que incluyen métodos de tratamiento para enfermedades y trastornos inflamatorios y/o fibróticos.
MX2022003159A 2019-09-16 2020-09-16 Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos. MX2022003159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
PCT/US2020/050973 WO2021055408A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022003159A true MX2022003159A (es) 2022-04-07

Family

ID=74868426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003159A MX2022003159A (es) 2019-09-16 2020-09-16 Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos.

Country Status (20)

Country Link
US (5) US11939373B2 (es)
EP (2) EP4031176A4 (es)
JP (2) JP2022548646A (es)
KR (1) KR20220079561A (es)
CN (1) CN114729036A (es)
AR (1) AR119979A1 (es)
AU (2) AU2020351138A1 (es)
BR (1) BR112022004776A2 (es)
CA (2) CA3154649A1 (es)
CL (1) CL2022000633A1 (es)
CO (1) CO2022003661A2 (es)
DO (1) DOP2022000058A (es)
EC (1) ECSP22022676A (es)
IL (1) IL291385A (es)
MX (1) MX2022003159A (es)
PE (1) PE20230090A1 (es)
TW (1) TW202124434A (es)
UY (1) UY38883A (es)
WO (2) WO2021055409A1 (es)
ZA (1) ZA202203272B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020351138A1 (en) 2019-09-16 2022-03-31 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2212411C2 (ru) * 1989-10-16 2003-09-20 Эмджен Инк. Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
RU2407752C2 (ru) * 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
US20080248050A1 (en) * 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
WO2012096960A2 (en) 2011-01-10 2012-07-19 The Regents Of The University Of Michigan Stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
KR101384360B1 (ko) * 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CN114163531A (zh) * 2015-08-19 2022-03-11 辉瑞公司 组织因子途径抑制剂抗体及其用途
BR112018012883A2 (pt) * 2015-12-22 2019-02-12 Abbvie Stemcentrx Llc novos anticorpos anti-upk1b e métodos de uso
AU2020351138A1 (en) 2019-09-16 2022-03-31 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease

Also Published As

Publication number Publication date
AR119979A1 (es) 2022-01-26
CL2022000633A1 (es) 2022-11-11
ECSP22022676A (es) 2022-05-31
CN114729036A (zh) 2022-07-08
US20220324957A1 (en) 2022-10-13
EP4031569A4 (en) 2023-10-18
JP2022548646A (ja) 2022-11-21
US20210079084A1 (en) 2021-03-18
CA3154649A1 (en) 2021-03-25
DOP2022000058A (es) 2022-08-31
US20220340655A1 (en) 2022-10-27
PE20230090A1 (es) 2023-01-16
US20230019680A1 (en) 2023-01-19
EP4031176A4 (en) 2023-11-29
AU2020348295A1 (en) 2022-04-07
UY38883A (es) 2021-04-30
KR20220079561A (ko) 2022-06-13
CA3154648A1 (en) 2021-03-25
US11939373B2 (en) 2024-03-26
JP2022547733A (ja) 2022-11-15
TW202124434A (zh) 2021-07-01
EP4031569A1 (en) 2022-07-27
CO2022003661A2 (es) 2022-04-08
WO2021055408A1 (en) 2021-03-25
EP4031176A1 (en) 2022-07-27
BR112022004776A2 (pt) 2022-06-21
AU2020351138A1 (en) 2022-03-31
US20240076367A1 (en) 2024-03-07
WO2021055409A1 (en) 2021-03-25
ZA202203272B (en) 2022-12-21
IL291385A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
TN2012000555A1 (en) Antibodies to human gdf8
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
JO3097B1 (ar) الأجسام المضادة c-Met
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
MX2022002682A (es) Anticuerpos anti-cd73.
MX2021014804A (es) Anticuerpo capaz de unirse a la linfopoyetina estromal timica y el uso del mismo.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2022005866A (es) Anticuerpos biparatopicos frente a cd73.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
EA202091569A1 (ru) Моноклональные антитела и способы их применения
MX2015012441A (es) Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.
MX2021000783A (es) Anticuerpos humanizados contra psma.
MX2022003159A (es) Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos.
CA3046446A1 (en) Therapies for treating inflammatory disorders
MX2019003019A (es) Anticuerpos anti-gm-csf y usos de los mismos.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).